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The treatment of diabetes has been mainly focused on maintaining normal blood glucose concentrations. Insulin 
and hypoglycemic agents have been used as standard therapeutic strategies. However, these are characterized 
by limited efficacy and adverse side effects, making the development of new therapeutic alternatives mandatory. 
Inhibition of glucose reabsorption in the kidney, mediated by SGLT1 or SGLT2, represents a promising thera-
peutic approach. Therefore, the aim of the present study was to evaluate the effect of thioglycosides on human 
SGLT1 and SGLT2. For this purpose, stably transfected Chinese hamster ovary (CHO) cells expressing human 
SGLT1 and SGLT2 were used. The inhibitory effect of thioglycosides was assessed in transport studies and 
membrane potential measurements, using α-methyl-glucoside uptake and fluorescence resonance energy trans-
fer, respectively. We found that some thioglycosides inhibited hSGLT more strongly than phlorizin. Specifically, 
thioglycoside I (phenyl-1’-thio-β-D-glucopyranoside) inhibited hSGLT2 stronger than hSGLT1 and to a larger 
extent than phlorizin. Thioglycoside VII (2-hydroxymethyl-phenyl-1’-thio-β-D-galacto-pyranoside) had a pro-
nounced inhibitory effect on hSGLT1 but not on hSGLT2. Kinetic studies confirmed the inhibitory effect of these 
thioglycosides on hSGLT1 or hSGLT2, demonstrating competitive inhibition as the mechanism of action. There-
fore, these thioglycosides represent promising therapeutic agents for the control of hyperglycemia in patients 
with diabetes. 
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1.  Introduction 
Diabetes mellitus is characterized by reduced 
insulin secretion from pancreatic β-cells (type 1 diabe-
tes) [1] or deficient insulin action (type 2 diabetes) [2], 
both causing an increase in blood glucose concentra-
tion. High blood glucose (hyperglycemia) represents 
the main pathogenic factor for the development of 
diabetic complications including coronary heart dis-
ease, retinopathy, nephropathy, and neuropathy [3, 4]. 
In addition, chronic hyperglycemia leads to progres-
sive impairment of insulin secretion and to insulin 
resistance of peripheral tissues (referred to as glucose 
toxicity) [1, 2, 5, 6]. As a consequence, the treatment of 
diabetes has been mainly focused on maintaining 
normal blood glucose levels. For that purpose either 
insulin or hypoglycemic agents have been used as 
standard therapeutic agents for the treatment of dia-
betes [7]. The mechanism of action of the anti-diabetic 
agents used for the treatment of type 2 diabetes, in-
clude increasing insulin release, improving glucose 
disposal, controlling hepatic glucose release or inhib-
iting intestinal glucose absorption [8]. 
Glucose is unable to diffuse across the cell mem-
brane and requires transport proteins [9]. The trans-
port of glucose into epithelial cells is mediated by a 
secondary active cotransport system, the so-
dium-D-glucose cotransporter (SGLT), driven by a 
sodium-gradient generated by the Na+/K+-ATPase. 
Glucose accumulated in the epithelial cell is further 
transported into the blood across the membrane by 
facilitated diffusion through GLUT transporters. 
SGLT belongs to the sodium/glucose cotrans-
porter family SLCA5 [10]. Two different SGLT iso-
forms, SGLT1 and SGLT2, have been identified to me-
diate renal tubular glucose reabsorption in humans. 
Both of them are characterized by their different sub-
strate affinity [11]. Although both of them show 59% 
homology in their amino acid sequence, they are func-
tionally different. SGLT1 transports glucose as well as 
galactose, and is expressed both in the kidney and in 
the intestine, while SGLT2 is found exclusively in the 
S1 and S2 segments of the renal proximal tubule [11]. 
As a consequence, glucose filtered in the glomerulus is 
reabsorbed into the renal proximal tubular epithelial 
cells by SGLT2, a low-affinity/high-capacity system, 
in S1 and S2 tubular segments. Much smaller amounts 
of glucose are recovered by SGLT1, as a Int. J. Med. Sci. 2007, 4 
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high-affinity/low-capacity system, in the distal seg-
ment of the tubule. 
Inhibition of glucose reabsorption in the kidney, 
mediated by the SGLT cotransport system, represents 
a promising therapeutic target for the control of hy-
perglycemia. The rationale to use SGLT as a target 
resulted from evidence obtained on several in vitro and 
in vivo animal studies [12-14] that show the efficacy of 
D-glucose analogues in inhibiting glucose transport 
[15]. This mechanism leads to increased urinary glu-
cose excretion and consequently reduces blood glu-
cose concentration. 
Tsujihara et al. [12] studies using phlorizin, an 
O-glucoside derivative were published in 1996. Phlor-
izin is the most studied substance to date [16]. It in-
hibits the activity of SGLT in the kidney leading to 
glycosuria [17]. Its clinical application; however, is 
restricted due to hydrolysis by β-glucosidases in the 
intestine [12]. To overcome this problem, phlorizin 
analogues have been chemical synthesized [13, 14]. 
The most commonly used is known as T-1095 
(3-(benzofuran-5-yl)-2',6'-dihydroxy-4'-methylpropio-
phenone      2'-O-(6-O-methoxycarbonyl-β-D-glyco- 
pyranoside) [18]. T-1095 is absorbed through the small 
intestine and converted into its active form, a specific 
inhibitor of renal SGLT, resulting in inhibition of glu-
cose reabsorption in the renal tubules [17, 19]. This 
compound was the first orally administered active 
agent with anti-hyperglycemic action that was pro-
posed for the treatment of diabetes mellitus, based on 
studies using diabetic animal models in rats [20-22] 
and mice [23].   
Since SGLT recognizes glucose analogues as a 
substrate, it is possible that other glucoside derivates 
could also inhibit the activity of SGLT. The role of 
glucose analogues on SGLT inhibition has been well 
demonstrated in vitro [19, 20] and in vivo animal mod-
els [17, 21-26]. Among these, thioglycosides are im-
portant to consider because they are not hydrolysed 
by β-glucosidases in the intestine and can be adminis-
tered orally [27]. 
Therefore, the aim of the present study was to 
evaluate the inhibitory effect of some thioglycosides 
synthesized in our laboratory on human hSGLT1 and 
hSGLT2 –as a potential therapeutic alternative for the 
control of hyperglycemia, particularly for people with 
diabetes. We chose to analyze the inhibitory effect of 
thioglucosides on human SGLT1 and 2 expressed in 
CHO cells due to their substrate selectivity and the 
kinetics of SGLT on different species [17, 28]. 
2.  Materials and Methods 
Cell Culture 
Stably transfected Chinese hamster ovary (CHO) 
cells, that express human SGLT1 or human SGLT2 
established in our laboratory [29], were seeded at a 
concentration of 1x103 cells/ml and maintained in 
culture for 2 days to allow the cells to form a confluent 
monolayer culture. For transport studies cells were 
seeded in 96-well microtiter scintiplates (PerkinElmer, 
Wiesbaden, Germany). For fluorescence resonance 
energy transfer (FRET) analysis cells were seeded in 
flat-bottom, poly-D-lysine black-wall, clear bottom, 
96-well plates (Becton Dickinson; Heidelberg, Ger-
many). 
Thioglycosides 
Thioglycosides are molecules in which a sugar 
group is bounded through its anomeric carbon to an-
other group via an S-glycoside bond. The alkylgluco-
side structure of thioglycosides allows the specific 
recognition of these substances by SGLT [30]. 
We analyzed seven thioglycosides (Table 1). 
Thioglycosides are hydrolysis-resistant, synthetic 
S-analogs of natural O-glucosides involved in the bio-
synthesis of chrysomelidial and salicin. These sub-
stances are synthesized and secreted as part of a de-
fense mechanism used by larvae of beetles (Chry-
somelidae). Their synthesis has been previously de-
scribed [31-33]. For the purpose of the present study 
the thioglycosides used were selected and grouped 
based on their differences in the aglycone binding site 
or in the glucose moiety (glucose-galactose). 
Determination of SGLT-mediated 
α-methyl-D-glucopyranoside uptake 
Sodium-dependent transport activity was deter-
mined by means of radioactive [14C] 
α-methyl-D-glucopyranoside ([14C]AMG, spec. radio-
activity 300 mCi/mmol) purchased from NEN (Bad 
Homburg, Germany), using the 96-well 
semi-automated method previously described in our 
laboratory [29]. AMG, a non-metabolizable glucose 
analogue that is selectively transported through SGLT 
but not through GLUT transporters, was used. 
Krebs-Ringer-Henseleit (KRH) solution containing 120 
mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 2.2 mM CaCl2, 
10 mM HEPES (pH 7.4 with Tris) was used to asses 
active glucose transport in the presence of sodium. For 
sodium free conditions, KRH solution containing 120 
mM N-methyl-glucamine (NMG) instead of NaCl 
(Na+) was used to assess the sodium-independent 
D-glucose transport (SGLT). The difference between 
the two experimental setups represents the so-
dium-dependent transport by hSGLT1 or hSGLT2. All 
chemicals were purchased from Sigma (Deisenhofen, 
Germany). 
Briefly, cells were rinsed three times with 200 μl 
KRH-Na+ or KRH-NMG. Then, 100 µl pro well of 
transport buffer containing KRH-Na+ or KRH-NMG 
plus [14C]AMG (0.1 µCi/µl) were added and the cells 
incubated for 1 h. At the end of the uptake period, 
[14C]AMG-uptake was stopped by adding 100 µl of 
ice-cold stop buffer (KRH-Na+, containing 0.5 mM 
phlorizin). Then, the cells were solubilized by adding 
100  μl of ATPlite substrate solution (PerkinElmer, 
Boston, USA), and luminescence for ATP detection 
was assessed using a MicroBeta Trilux (PerkinElmer). 
A standard curve was used to determine the amount 
of ATP in mg of protein measured from the number of 
cells per well. After 24 h, the microtiter plate was 
taken for scintillation counting of radioactive 
[14C]AMG using a MicroBeta Trilux (PerkinElmer). Int. J. Med. Sci. 2007, 4 
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Subsequently, the mean counts per minute (cpm) were 
calculated and converted to picomoles (pmol). Uptake 
was expressed as pmol/mg/h. Sodium-dependent 
[14C]AMG uptake was calculated by subtracting up-
take under sodium-free conditions from the uptake 
obtained in the presence of sodium. Results are ex-
pressed as percent of inhibition from AMG uptake in 
CHO cells expressing hSGLT1 or hSGLT2 but not ex-
posed to thioglycosides. IC50 values were calculated 
using the Kinetic Enzyme Module (SigmaPlot 8.02, 
Systat Software, Erkrath, Germany). 
Table 1 Thioglycosides used to evaluate their inhibitory effect on hSGLT1 and hSGLT2 
 
 
 
Measurement of SGLT-mediated thioglycoside 
translocation 
SGLT-mediated translocation of thioglycosides 
was determined by assessing the membrane depolari-
zation using fluorescence resonance energy transfer 
(FRET). Cells were incubated for 48 h at 37°C in a 5% 
CO2 in growth medium. Subsequently, cells were 
washed with 0.2 ml Dulbecco´s phosphate-buffered 
saline (PBS; Invitrogen, Karlsruhe, Germany) and then 
incubated with 0.1 ml of a solution containing 5 µM 
CC2-DMPE and 0.02% pluronic acid in PBS. After in-
c u b a t i o n  i n  t h e  d a r k  f o r  3 0  m i n  a t  2 5 ° C ,  c e l l s  w e r e  
washed twice with 0.2 ml PBS. After that, cells were 
incubated in the dark at 25°C for 30 min with 0.1 ml of 
a solution containing 1 µM DiSBAC2(3). At the end of 
the incubation period the wells were excited by 390 
nm. Fluorescence emission was recorded at 460 and 
580 nm. After a 20 sec baseline reading, 0.1 ml of PBS 
containing 10 µM of the compound investigated was 
added, and the fluorescence signal was recorder for 40 
sec. The change in fluorescence was calculated as the 
ratio of F/ F0 equal to = [(A460/A580)/(I460/I580)], where 
A and I represent the readings after or before addition 
each thioglucoside, respectively. For I, the readings Int. J. Med. Sci. 2007, 4 
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from 2-5 sec were averaged; and for A, readings from 
3 sec after the signal had reached a plateau level (usu-
ally within 2-5 sec) were also averaged. FRET values 
were expressed as relative fluorescence units (RFU). 
Statistical analysis 
Data are expressed as mean values ± standard 
deviation (SD). Results of [14C]AMG uptake in the 
stably transfected CHO cells treated with each 
thioglycoside were compared with [14C]AMG uptake 
in CHO cells not exposed to thioglycoside (control 
cells) using independent t-test analysis, and expressed 
as percent inhibition from uptake in control cells. The 
change in fluorescence resonance energy transfer 
(FRET) signal was normalized to the values obtained 
from non-transfected CHO cells, and compared to 
control cells using independent t-test analysis. Statis-
tical significance was assumed at p level <0.05 level. 
SigmaPlot software version 8.02 (Systat Software, Er-
krath, Germany) was used for statistical analysis. 
3.  Results 
Inhibition of SGLT transport activity 
The thioglycosides investigated in this study are 
shown in Table 1. Figure 1 shows the inhibitory effect 
of each thioglycoside (10 µM) and phlorizin (10 µM) 
on sodium-dependent AMG-uptake in hSGLT1 and 
hSGLT2, as compared to control CHO cells. The AMG 
concentration was 3 µM. As expected all thioglyco-
sides inhibited sodium-dependent AMG-uptake. In 
most cases the inhibitory effect was similar both with 
regard to the two transporters (hSGLT1 and hSGLT2) 
and to the inhibition exerted by the same concentra-
tion of phlorizin, exceptions are thioglycosides I and 
VII. Thioglycoside I inhibited hSGLT2 stronger than 
hSGLT1 and to a larger extent than phlorizin; while 
thioglycoside VII had a more pronounced inhibitory 
effect on hSGLT1 than on hSGLT2 (p < 0.01). 
The inhibitory effect of thioglycoside I was 
stronger for hSGL2 than for hSGLT1, with values of 
66.7 ± 3.2 % and 23.2 ± 2.8 %, respectively. In contrast, 
thioglycoside VII had a higher inhibitory effect on 
hSGLT1 than hSGLT2 with values of 57.9 ± 2.3% and 
26.7 ± 1.9 %, respectively. These values were higher 
compared to those obtained with phlorizin (10 µM), 
which were equivalent to 34.8 ± 1.6% inhibition for 
hSGLT1 and 33.4 ± 1.8% inhibition for hSGLT2. These 
findings suggest that thioglycosides I and VII have a 
strong inhibitory effect on hSGLT2 and hSGLT1, re-
spectively. 
To analyze further the inhibitory effect on so-
dium-dependent AMG-uptake of each thioglycoside, 
IC50 values were determined. As shown in Table 2, the 
IC50 values of all seven thioglycosides ranged from 9 
µM to 37 µM for hSGLT1 and from 10 µM to 88 µM for 
hSGLT2. The values obtained by the thioglycosides 
were similar to those obtained with phlorizin, which 
were equivalent to 42 µM and 28 µM for hSGLT1 and 
hSGLT2, respectively. The inhibition of the so-
dium-dependent AMG-uptake for all thioglycosides 
was similar to that obtained using phlorizin, suggest-
ing a similar inhibitory effect for all these substances. 
Figure 2 shows the IC50 curves for thioglycosides I and 
VII. Thioglycoside I showed IC50 values of 30 µM for 
hSGLT1 and 10 µM for hSGLT2, while thioglycoside 
VII showed IC50 values of 15 µM for hSGLT1 and 88 
µM for hSGLT2. These data confirm the strong inhibi-
tory effects of thioglycoside I and VII on hSGLT2 and 
hSGLT1, respectively. This finding suggests that these 
two thioglycosides may be promising anti-diabetic 
agents, based on their strong inhibitory effects on 
hSGLT. 
 
 
 
 
 
Figure 1 Effect on sodium-dependent [
14C]AMG-uptake ob-
tained in hSGLT1 or hSGLT2 treated with thioglycosides (10 
µM each) or phlorizin (10 µM). Results are expressed as percent 
of inhibition based on uptake in CHO cells expressing hSGLT1 
or hSGLT2 not exposed to thioglycosides (control cells). Blue 
and red bars represent hSGLT1 and hSGLT2, respectively. 
Results are the mean of six different experiments. Error bars 
represents standard deviations. * p < 0.01 shows significantly 
higher inhibition of sodium-dependent AMG uptake in treated 
cells as compared to control cells. Control uptake in CHO cells 
expressing hSGLT1 was 735 pmol/mg/h ± 22 pmol/mg/h and in 
CHO cells expressing hSGLT2 was 342 pmol/mg/h ± 15 
pmol/mg/h. 
 
 
Table 2 Inhibitory concentration (IC50) of thioglycosides on 
hSGL1 and hSGLT2, values are expressed as µM. 
 hSGLT1  hSGLT2 
Thioglycoside    
I 30  10 
II 37  42 
III 11  40 
IV 35  52 
V 9  32 
VI 12  52 
VII 15  88 
Phlorizin 42  28 
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Figure 2 Effect of thioglycoside I and thioglycoside VII on sodium-dependent AMG uptake on CHO cells expressing hSGLT1 (A) 
and CHO cells expressing hSGLT2 (B) was determined by IC50 assessment. Different concentrations of thioglycoside I and VII in 
log scale were plotted against [
14C]AMG uptake as percentage of CHO control cells. The curves for hSGLT 1 and 2 on each cell type 
were constructed from results from eight different concentrations ranging from 10
-7 to 5x10
-4. The IC50 values of phlorizin are shown 
as a known reference inhibitory effect. 
 
SGLT Translocation Activity 
In order to investigate whether the thioglyco-
sides were translocated into the cells by the SGLT co-
transport system, their effect on membrane potential 
was measured. Changes in membrane potential in-
duced by each thioglycoside (10 µM) were determined 
by fluorescence resonance energy transfer (FRET). 
FRET values were normalized using the change in 
fluorescence signal obtained from non-transfected 
CHO cells. A fluorescence response ratio lower than 1 
indicates that these compounds were not significantly 
transported, while a ratio greater than 1 demonstrates 
transport across the plasma membrane mediated by 
SGLT. To validate this assay, studies with D-glucose 
as a substrate of SGLT were performed and the corre-
lation of sodium-dependent D-glucose uptake to 
sugar-induced cell membrane depolarization, as 
measured by FRET, was calculated. As shown in Fig-
ure 3, a statistically significant linear relation between 
the changes in membrane potential and the transport 
activity of the cells was observed with a correlation 
coefficient of 0.92, validating the experimental ap-
proach chosen. 
 Int. J. Med. Sci. 2007, 4 
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Figure 3 Correlation of sodium-dependent AMG-uptake to 
sugar-induced cell membrane depolarization is shown. The 
correlation coefficient of 0.92 demonstrates a strong linear 
relationship between the two variables (p < 0.001). 
 
 
 
Figure 4 Changes in cell membrane potential induced by 
D-glucose, thioglycosides I and VII (10 <mM each), and 
phlorizin were assessed by fluorescence resonance energy 
transfer (FRET) an expressed as relative fluorescence units 
(RFU). Blue and red bars represent hSGLT1 and hSGLT2, 
respectively. The change in FRET signal was normalized to the 
values obtained from non-transfected CHO cells (controls). 
Results are the mean of six different experiments. Error bars 
represents standard deviations. * p < 0.01 shows significantly 
higher induction of cell membrane depolarization in treated cells 
as compared to control cells (not exposed to thioglycosides). 
 
Figure 4 shows the results in membrane potential 
induced by D-glucose, thioglycosides I and VII and 
phlorizin. As expected, the maximal effect was ob-
served with D-glucose with FRET values of 5.62 and 
2.29 for hSGLT1 and hSGLT2, respectively. Thioglyco-
side I showed a small but significant change in cell 
membrane depolarization with a fluorescence signal 
ratio of 1.15 for hSGLT1 and 1.29 for hSGLT2 (p <0.01). 
Thioglycoside VII also showed a significant induction 
of cell membrane depolarization with a fluorescence 
ratio of 1.32 for hSGLT2 (p <0.01) while no change was 
observed for hSGLT1. In contrast, phlorizin was not 
transported by either hSGLT, as shown by FRET val-
ues of 0.09 and 0.18 for hSGLT1 and hSGLT2, respec-
tively. These data clearly show the electrogenic uptake 
of thioglycoside I and VII across the plasma mem-
brane. 
4.  Discussion 
The sodium-dependent glucose transport (SGLT) 
system represents an excellent target for the develop-
ment of innovative substances to effectively manage 
hyperglycemia, thus preventing the adverse complica-
tions of glucose toxicity observed in diabetes. The re-
sults of the present study suggest that some thioglyco-
sides have a therapeutic potential for the control of 
blood glucose levels. This promising effect resulted 
from the strong inhibitory effect of thioglycosides I 
and VII we observed on sodium-dependent AMG up-
take in CHO cells expressing hSGLT2 and hSGLT1, 
respectively. 
Current strategies to treat diabetes are mainly 
focused in different interventions directed to improve 
glucose disposal (using insulin sensitizers like met-
formin), to reduce insulin resistance (using glitazones 
like rosiglitazone and pioglitazone) and/or to control 
hepatic glucose release (using biguanides) [7]. In addi-
tion, manipulation of insulin through exogenous insu-
lin administration or increase of endogenous insulin 
production, using sulfonylureas and meglitinides, are 
also used to treat diabetes [8]. Another diabetes 
therapeutic approach is based on reducing intestinal 
glucose absorption using α-glucosidase inhibitors 
such as acarbose, miglitol and voglibose [34]. 
α-glucosidase are key enzymes involved in the diges-
tion of carbohydrates. 
Inhibition of glucose transport in the kidney 
through O-glycosides represents a different mecha-
nism of action from other hypoglycemic agents. 
However, until now it has not been applied to clinical 
practice because absorption of these 
anti-hyperglycemic substances (namely phlorizin) is 
low when administered orally. Studies using alkyl 
thioglycosides have demonstrated that these sub-
stances have a higher affinity for SGLT than 
O-glucosides [35]. Furthermore, thioglycosides are not 
metabolized in the intestine [27]. Therefore, a chemical 
reaction to convert the substance in its active form, 
after intestinal absorption like in the case of 
O-glucosides, is not necessary. In addition, alkyl 
thioglucosides have demonstrated to posses a high 
renal selectivity [36]. These characteristics make 
thioglycosides good candidate substances for the con-
trol of hyperglycemia. However, their inhibitory effect 
on a model system for sodium-dependent glucose 
transport has not been determined, thus the aim of the 
present study. 
We tested whether some alkyl thioglucosides 
would have the ability to reduce glucose transport 
through hSGLT1 or hSGLT2 as shown by AMG up-
take studies. Our results demonstrate a strong inhibi-Int. J. Med. Sci. 2007, 4 
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tory effect of thioglycoside I (phenyl-1’-thio-β-D--
glucopyranoside) on hSGLT2 and thioglycoside VII 
(2-hydroxymethyl-phenyl-1’-thio-β-D-galactopyranosi
de) on hSGLT1. Studies in animals [23, 37] and in hu-
mans [38] have demonstrated a higher renal glucose 
reabsorption in diabetes compared to non diabetic 
conditions. This has been attributed to an increased 
expression of GLUT2 transport protein or an increased 
glomerular filtration rate [39], which may contribute 
to enhanced glucose transport across the contra lu-
minal membrane and exacerbated hyperglycemia. The 
reduction in glucose uptake at the luminal site by in-
hibition of SGLT would effectively decrease glucose 
reabsorption in the proximal tubule and contribute to 
control the increased blood glucose levels observed in 
diabetes. This assumption supports the notion of us-
ing SGLT inhibitors as a means to control circulating 
levels of glucose. The selective inhibition of hSGLT2 
by thioglycoside I, which is responsible for most of the 
reabsorption of glucose in the kidney, represents a 
promising alternative for the control of hyperglyce-
mia. 
It has been shown previously that SGLT1 has a 
lower affinity to phlorizin than SGLT2 [40]. Based on 
the IC50 values obtained with phlorizin in the CHO 
cells expressing hSGLT1 or hSGLT2, it can be con-
cluded that the method we use is suitable to differen-
tiate between hSGLT1 and hSGLT2. As a consequence, 
the data obtained by thioglucoside I 
(phenyl-1’-thio-β-D-glucopyranoside) and VII 
(2-hydroxymethyl-phenyl-1’-thio-β-D-galactopyranosi
de) on inhibition of AMG uptake represent important 
new evidence to be studied further as an alternative 
for the control of blood glucose levels in diabetic 
models. 
The mechanism of action by which thioglyco-
sides exert this inhibitory effect may be different from 
that of other oral anti-diabetic agents. Studies using 
rat enterocytes, where the process of glucose transport 
is very similar to that in the renal proximal tubule, 
have demonstrated that glucagon increases 
SGLT-mediated glucose uptake [41]. Glucagon also 
promotes GLUT-mediated glucose transport across 
the proximal tubule [42]. This information suggests 
that renal glucose reabsorption may be regulated by 
glucagon and that the direct inhibition of SGLT may 
represent a viable mechanism for the control of hy-
perglycemia that is independent from the well known 
hormonal regulation of blood glucose levels. The 
change in membrane potential induced by 
thioglycosides I and VII we found, suggests a 
competitive mechanism in which each thioglycoside 
binds to SGLT but are not transported. 
Our results also suggest the following struc-
ture-activity relationship. We found that thioglucoside 
I (phenyl-1’-thio-β-D-glucopyranoside) significantly 
inhibited hSGLT2-mediated AMG-uptake but to lesser 
extent hSGLT1, suggesting that differences in the 
aglycon binding site play an important role in the in-
hibitory effect of this substance. In contrast, differ-
ences in the sugar binding site resulted in an preferen-
tial inhibitory effect of thioglycoside VII on hSGLT1 
which accepts D-galactose more avidly than D-glucose. 
This suggests that the glucose moiety may enable dif-
ferent thioglycosides to selectively inhibit active glu-
cose transported mediated by either hSGLT1 or 
hSGLT2. 
Phenyl-O-glucosides have been shown to behave 
as transported substrates, non-transported inhibitors 
or non-interacting compounds, depending on the na-
ture and position of the chemical group in the phenyl 
ring [43]. According to our studies the translocation of 
thioglycosides seems to be insignificantly, but has to 
be tested further when radioactively labelled deriva-
tives become available. 
The 96-well method used in the present study [29] 
has the advantage to be able to analyze simultane-
ously several substances and more importantly, the 
small concentrations of a given substance required 
make it possible to test a wide range of substances. 
However, it must be noted that for hydrophobic 
compounds due to absorption to the cells and their 
support, such as thioglycosides, the exact amount of 
the substance present in a solution cannot be quanti-
fied. Thus the IC50 values probably are shifted to 
higher apparent concentrations. 
One of the advantages of using glucose ana-
logues (such as T-1095) to control hyperglycemia has 
been reported in studies with diabetic rats, in which a 
significant reduction in diabetic neuropathy has been 
shown [25]. This finding supports the use of other 
glucose analogues, such as the thioglycosides we 
studied, for the treatment of hyperglycemia. In con-
trast, a possible side effect of thioglycoside treatment 
is glycosuria. This side effect may resemble the renal 
glycosuria observed in non-functioning mutations of 
the SGLT2 gene, leading to a complete absence of re-
nal tubular glucose reabsorption accompanied by in-
creased urinary glucose excretion [44]. However, it has 
been shown that long term renal glycosuria is not a 
causative factor for the development of renal damage 
[44]. Additional studies are needed to confirm the 
benefits and adverse effects of thioglycoside treatment 
in humans. 
In conclusion, thioglycosides represent promis-
ing therapeutic agents for the control of hyperglyce-
mia. In addition, thioglycosides can be used orally, 
based on its transport in the intestine across the 
plasma membrane through SGLT1. Thioglycosides 
have a high renal specificity that is associated with a 
strong competitive inhibitory effect of so-
dium-D-glucose cotransporter system mediated by 
SGLT2. The clinical application of these thioglycosides, 
however, needs to be further analyzed. Nonetheless, 
our findings provide the foundation for future studies 
with the objective to determine the clinical applica-
tions of thioglucosides in human diseases like diabe-
tes. 
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